Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Scrip Team
The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.
The open-label Phase IIb data link setrusumab, licensed from Novartis, to improvements in bone density, offering encouragement for Mereo ahead of a critical upcoming readout for its lead program.
After two years on clinical hold, the French biotech has resolved quality and pharmacovigilance problems that forced it to suspend studies of masitinib, moving it a step closer to restarting trials in its home country.